PubMed Central , Circulation , vol
The reason this question gets asked so often is that a large share of GLP-1 patch advertising is built around female-coded weight-loss anxiety: hormonal belly fat, metabolic slowdown after 40, stubborn weight that "diet and exercise won't touch." Those frustrations are real and often physiologically grounded
Alongside GLP-1 Medications GLP-1 drugs produce significant fat loss, which places increased demands on the liver
It was removed from compounding Category 2 in September 2024, and PCAC voted against it in December 2024 , leaving no current 503A compounding pathway
J Lipid Res 56(3):489501
Retrieved from Preiss, D., Dawed, A., Welsh, P., et al